 |
|
|
| |
Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces
Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH
|
| |
| |
Reported by Jules Levin
EASL - International Liver Congress™, 19-23 April 2017, Amsterdam, the Netherlands
Susanne Schuster,1,2 Matthew D. McGeough,1 Casey D. Johnson,1 Anna Zagorska,3 Grant Budas,3 Harold M. Hoffman,1 Ariel E. Feldstein1
1UC San Diego, La Jolla, California, USA; 2Pediatric Research Center, University Hospital for Children and Adolescents, Universität Leipzig, Germany; 3Gilead Sciences, Inc., Foster City, California
EASL: Treatment with Selonsertib, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), Reduces Hepatic Phospho-p38 Expression and Markers of Hepatocellular Apoptosis and Necrosis in Patients with NASH - (05/23/17)
EASL: Pharmacokinetics of Selonsertib, GS-9674, and/or GS-0976 in Combination in Healthy Subjects - (05/23/17)
GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)
FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)
EASL: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Suppression of Hepatic De Novo Lipogenesis and Significant Improvements in MRI-PDFF, MRE and Markers of Fibrosis after 12 Weeks of Therapy in Patients with NASH - (05/23/17)
References
1. Wree A, et al. Hepatology 2014;59:898-910;
2. Wree A, et al. J Mol Med (Berl) 2014;92:1069-82;
3. McGeough M, et al. J Immunol 2012;189:2707-11;
4. Ichijo H, et al. Science 1997;275:90-4;
5. Vallerie SN, Hotamisligil GS. Science Transl Med 2010;2:60-5;
6. Zhao G, et al. Gut 2014;63:1159-72.
|
| |
|
|
|
|
|
